Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CT-P47 Auto-injector vs Pre-filled Syringe PK Study
NCT05617183Phase 1Unknown
- Sponsor
- Celltrion
- Start
- Nov 2022
- Primary completion
- Apr 2023
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of tocilizumab in rheumatoid arthritis (RA) (2 arms), sponsored by Celltrion. Primary endpoints: Area Under the Concentration-time Curve From Time Zero to Infinity at Day 43 and Maximum Serum Concentration at Day 43. Status: unknown.
02
Drugs
tocilizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT05617183.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05617183.